Cost-effectiveness of an in-development adult-formulated pneumococcal vaccine in older US adults.

ABSTRACT:

Introduction

CDC pneumococcal vaccination recommendations for older adults now include either 15- or 20-valent pneumococcal conjugate vaccine (PCV15/PCV20). However, an in-development 21-valent vaccine (PCV21), formulated based on adult pneumococcal disease epidemiology, could substantially increase coverage of disease-causing pneumococcal serotypes, particularly in Black older adults, who are at greater risk. The potential public health impact and cost-effectiveness of PCV21 compared to currently recommended vaccines in older adults is unclear.

Methods

A Markov decision model compared current pneumococcal vaccination recommendations to PCV21 use in Black and non-Black 65-year-old cohorts. CDC Active Bacterial Core surveillance data informed population and serotype-specific

SUBMITTER: Wateska AR 

PROVIDER: S-EPMC10330932 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature